SONGDO, South Korea,
July 11, 2020 /PRNewswire/ -- Samsung
Biologics (207940.KS) has further expanded its partnership with
STCube through an additional development and manufacturing service
agreement of STM418, an anti-PD1 immuno-oncology candidate.
STM418 received much attention from the biopharma industry
earlier this year upon publication in the Cancer Research
Journal. Through preliminary studies, STCube reported that STM418,
which selectively masks glycosylation site N58 on PD-1, potently
inhibits PD-1/PD-L1 binding to enhance anti-tumor immunity.
Under the development and manufacturing agreement, Samsung
Biologics will offer full scope of CDO services from cell line
development, process development, non-clinical & clinical
material manufacturing, to IND submission for global clinical
trials of STM418.
"We look forward to getting fast IND approval for our novel PD-1
antibody through this extended partnership with Samsung Biologics,
a world-class CDMO," said Hyun-jin Jung, CEO of STCube. "We will
commence global clinical trials to prove the enhanced efficacy
compared to existing PD-1 antibodies."
Samsung Biologics CDO business has been growing at a tremendous
pace since its launch in 2018 with a high number – over 50% – of
clients returning for additional business collaboration. STCube,
another returning client, had entered into its first CDO
partnership with Samsung Biologics in March this year for an
immuno-oncology molecule, STT-003.
"We are grateful to STCube for this extended partnership and for
recognizing our development expertise and our dedication to
bringing client products to market faster and better," said Dr.
Tae Han Kim, CEO of Samsung
Biologics.
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO
offering state-of-the-art contract development, manufacturing, and
laboratory testing services. With a flawless regulatory approvals
record, the largest capacity at a single site, and the fastest
throughput, Samsung Biologics is an award-winning partner of choice
and is uniquely able to support the development and manufacturing
of biologics products at every stage of the process while meeting
the evolving needs of biopharmaceutical companies worldwide. For
more information, visit www.samsungbiologics.com.
About STCube, Inc.
STCube, Inc. (KRX: 052020.KQ), headquartered in Seoul, South Korea, is an innovative global
biopharmaceutical company devoted to developing the next generation
of anti-cancer immunotherapy. For more information, visit
www.stcube.com
Media Contact
Claire Kim
cair.kim@samsung.com
View original
content:http://www.prnewswire.com/news-releases/samsung-biologics-signs-additional-development-and-manufacturing-agreement-with-stcube-301091645.html
SOURCE Samsung Biologics